Earnings Call Intelligence Subscribe
Home › Call Sheets › JNJ › Q2'26
Call sheet · Q2'26

Johnson & Johnson (JNJ)

Q2'26 earnings call · held July 15, 2026 · compared with the Q1'26 call · management-credibility review
5/12
Disclosure score
2 high, 4 medium, 2 low flags
Financial quality
Bottom line
The sleeper story is that J&J's MedTech business is structurally broken, with Abiomed in decline, China channel stuffing masking EP weakness, and management already walking back H2 recovery promises just one quarter after making them. The $100B revenue milestone grabs headlines but masks that three of four MedTech segments missed plan and Innovative Medicine is carrying the entire company. The binding constraint is that Abiomed won't recover until PROTECT IV data in 2027, creating an 18-month headwind for their highest-margin MedTech segment while they're trying to separate orthopedics. Management's tell: 'We see this as a near-term dynamic' for Abiomed while simultaneously admitting recovery won't happen until 'we leave this year into next year.' My view changes if ICOTYDE exceeds 25,000 patients by year-end or if they provide transparent MedTech segment targets showing a path to recovery without Abiomed.

The 30-second version

  • The Street is missing that J&J just quietly admitted Abiomed won't recover until PROTECT IV data in 2027
  • The obvious $100B milestone masks deteriorating MedTech quality with EP inventory stuffing in China
  • ICOTYDE's 10,000 patient number is actually concerning given the hype

What changed this quarter

MetricQ1'26Q2'26Change
Total Revenue$24.1B (6.4% YoY)$25.3B (5.6% YoY)80 bps deceleration despite easier comp
Adjusted EPS$2.70 (-2.5% YoY)$2.90 (+4.7% YoY)Return to growth but below historical
Net Income$5.2B$5.5B+5.8% sequential
Operating Income (Adjusted)32.5% margin34.2% margin+170 bps sequential improvement
Innovative Medicine Revenue$15.4B (7.4% YoY)$16.4B (6.8% YoY)60 bps deceleration
Innovative Medicine Margin39.7%42.5%+280 bps sequential recovery
MedTech Revenue$8.6B (4.6% YoY)$8.9B (3.6% YoY)100 bps deceleration
MedTech Margin22.3%22.0%30 bps compression
Free Cash Flow YTD$1.5B (Q1 only)$8.7B (H1 total)$7.2B Q2 generation
DARZALEX Sales$4.0B (17.8% YoY)$4.0B+ (17.6% YoY)Stable at $4B quarterly run rate

Accountability tracked

8 new promises made5 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full JNJ Q2'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.